Recently, WHOOP, the human performance company, and Ashley Addiction Treatment (Ashley), a nationally-recognized leader in evidence-based treatment of substance use disorders, announce a new research partnership to study recovery and relapse by leveraging objective health data from WHOOP Unite alongside subjective patient feedback. In support of these efforts, WHOOP launched the WHOOP Gateway, an innovative hardware and software solution that enables healthcare providers to tap into 24/7 patient physiological insights.
Ashley is the first customer to use WHOOP Unite in conjunction with the WHOOP Gateway for cutting-edge patient support and research. The WHOOP Gateway uses Bluetooth to retrieve biometric data from WHOOP wearable technology and transmit it to WHOOP Unite without the need for a mobile phone. WHOOP Unite is a comprehensive solution dedicated to supporting organizations with coaching, insights and health programs. The platform helps leaders make policy and protocol changes based on the aggregated data of individual end users.
“At Ashley, we are passionate about providing state-of-the-art care to every person who walks through our doors, which is why advancing the way we conduct research and invest in technology remains at the forefront of everything we do,” said Greg Hobelmann, M.D., M.P.H., co-CEO and president of Ashley. “WHOOP Unite provides a holistic view of patients’ biometric data impacting their treatment, and WHOOP Gateway is the critical link to collecting a large dataset since our patients do not have access to mobile phones during treatment. The ability to gather this type of pivotal health information is a game-changer for our industry and Ashley’s one-of-its-kind database that’s enabling us to change the face of addiction medicine.”
According to the National Institute on Drug Abuse, up to an estimated 60 percent of individuals relapse while in recovery. Ashley is building and expanding its research efforts in collaboration with the faculty of The Johns Hopkins University School of Medicine to better understand the cause of relapse and identify new treatment protocols to reduce stress triggers while leading to better outcomes for its patients.
“We are excited to partner with Ashley in our research to better the lives of substance use disorder patients,” added Andrew Huhn, Ph.D., an associate professor at The Johns Hopkins University School of Medicine who is overseeing the Internal Review Board (IRB) study with patients in Ashley’s facilities. “This research leveraging WHOOP Unite insights lays the groundwork for incorporating biometric assessments into routine care, and ultimately, creating a precision medicine model for addiction treatment.”
To further its ability to support organizations like Ashley as well as patients, providers and payers across the healthcare ecosystem, WHOOP recently hired Dr. Patrick Carroll, M.D., the company’s first Chief Medical Officer. Dr. Carroll previously served as Chief Medical Officer of the virtual care company Vida Health and the telehealth company Hims-Hers. Prior to that, he served as Group Vice President and Chief Medical Officer of Walgreens.
“WHOOP Unite is pushing the healthcare industry forward with its innovative solutions like the WHOOP Gateway and efforts to improve patient outcomes as exemplified by this partnership with Ashley Addiction Treatment,” said Dr. Patrick Carroll, chief medical officer at WHOOP. “WHOOP has the power to positively impact the health of its members and transform the way we approach wellness at scale.”
Healthcare Business Today is a leading online publication that covers the business of healthcare. Our stories are written from those who are entrenched in this field and helping to shape the future of this industry. Healthcare Business Today offers readers access to fresh developments in health, medicine, science, and technology as well as the latest in patient news, with an emphasis on how these developments affect our lives.